Analysts Set UroGen Pharma Ltd. (NASDAQ:URGN) PT at $43.70

UroGen Pharma Ltd. (NASDAQ:URGN) has been given an average recommendation of “Buy” by the six research firms that are covering the company, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $39.20.

A number of brokerages have issued reports on URGN. LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a research report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 target price on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Tuesday, February 18th.

Insiders Place Their Bets

In related news, insider Mark Schoenberg sold 4,551 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the sale, the insider now owns 145,666 shares of the company’s stock, valued at $1,622,719.24. This represents a 3.03 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the transaction, the general counsel now directly owns 26,468 shares in the company, valued at $294,853.52. This represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in UroGen Pharma by 4.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company’s stock valued at $231,000 after buying an additional 969 shares during the last quarter. Rhumbline Advisers lifted its position in UroGen Pharma by 2.8% in the 4th quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock valued at $546,000 after purchasing an additional 1,402 shares during the last quarter. MetLife Investment Management LLC lifted its position in UroGen Pharma by 13.6% in the 4th quarter. MetLife Investment Management LLC now owns 22,766 shares of the company’s stock valued at $242,000 after purchasing an additional 2,727 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in UroGen Pharma by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company’s stock valued at $996,000 after purchasing an additional 3,024 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in UroGen Pharma by 90.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after purchasing an additional 3,856 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors.

UroGen Pharma Price Performance

UroGen Pharma stock opened at $10.08 on Wednesday. The firm has a fifty day moving average of $10.70 and a 200-day moving average of $12.13. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. UroGen Pharma has a 52-week low of $9.78 and a 52-week high of $20.70. The firm has a market capitalization of $236.38 million, a P/E ratio of -3.20 and a beta of 1.08.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.